Clostridium difficile:: Emergence of hypervirulence and fluoroquinolone resistance

被引:64
作者
Razavi, B.
Apisarnthanarak, A. [1 ]
Mundy, L. M.
机构
[1] Thammasart Univ Hosp, Fac Med, Div Infect Dis, Pathum Thani 12000, Thailand
[2] W Georgia Med Ctr, Dept Med, La Grange, GA USA
[3] Clark Holder Clin, La Grange, GA USA
[4] St Louis Univ, Sch Publ Hlth, St Louis, MO 63103 USA
关键词
D O I
10.1007/s15010-007-6113-0
中图分类号
R51 [传染病];
学科分类号
100401 ;
摘要
Clostridium difficile is a well-known cause of sporadic and healthcare-associated diarrhea. Multihospital outbreaks due to a single strain and outbreaks associated with antibiotic selective pressure, especially clindamycin, have been well documented. Severe cases and fatalities from C. difficile are uncommon. The recent global emergence of a hypervirulent strain containing binary toxin (Toxinotype III ribotype 027), with or without deletion in a regulatory gene (tcdC gene), together with high-level resistance to third generation fluoroquinolones, has been associated with increased morbidity and mortality. Although the defective regulatory gene locus is associated with increased toxin production in vitro, the in vivo significance of this mutation and of the binary toxin remains undefined. To date, treatment strategies have not evolved in response to the emergence of this hypervirulaent strain. We provide a critical, quantitative summary of the evolving clinical and molecular epidemiology of C. difficile along with implications relevant to future treatment strategies.
引用
收藏
页码:300 / 307
页数:8
相关论文
共 96 条
[1]   Recurrent Clostridium difficile colitis:: Case series involving 18 patients treated with donor stool administered via a nasogastric tube [J].
Aas, J ;
Gessert, CE ;
Bakken, JS .
CLINICAL INFECTIOUS DISEASES, 2003, 36 (05) :580-585
[2]   Clostridium difficile vaccine and serum immunoglobulin G antibody response to toxin A [J].
Aboudola, S ;
Kotloff, KL ;
Kyne, L ;
Warny, M ;
Kelly, EC ;
Sougioultzis, S ;
Giannasca, PJ ;
Monath, TP ;
Kelly, CP .
INFECTION AND IMMUNITY, 2003, 71 (03) :1608-1610
[3]   Correlation of disease severity with fecal toxin levels in patients with Clostridium difficile-associated diarrhea and distribution of PCR ribotypes and toxin yields in vitro of corresponding isolates [J].
Åkerlund, T ;
Svenungsson, B ;
Lagergren, Å ;
Burman, LG .
JOURNAL OF CLINICAL MICROBIOLOGY, 2006, 44 (02) :353-358
[4]  
ALBARRAK A, 1999, CAN COMMUN DIS REP, V1, P65
[5]   CLOSTRIDIUM-DIFFICILE INFECTION ASSOCIATED WITH ANTINEOPLASTIC CHEMOTHERAPY - A REVIEW [J].
ANAND, A ;
GLATT, AE .
CLINICAL INFECTIOUS DISEASES, 1993, 17 (01) :109-113
[6]   Adjunctive intracolonic vancomycin for severe Clostridium difficile colitis:: Case series and review of the literature [J].
Apisarnthanarak, A ;
Razavi, B ;
Mundy, LM .
CLINICAL INFECTIOUS DISEASES, 2002, 35 (06) :690-696
[7]   Effectiveness of environmental and infection control programs to reduce transmission of Clostridium difficile [J].
Apisarnthanarak, A ;
Zack, JE ;
Mayfield, JL ;
Freeman, J ;
Dunne, WM ;
Little, JR ;
Mundy, LM ;
Fraser, VJ .
CLINICAL INFECTIOUS DISEASES, 2004, 39 (04) :601-602
[8]   Severe Clostridium difficile colitis:: The role of intracolonic vancomycin? [J].
Apisarnthanarak, A ;
Khoury, H ;
Reinus, WR ;
Crippin, JS ;
Mundy, LM .
AMERICAN JOURNAL OF MEDICINE, 2002, 112 (04) :328-329
[9]   Prevalence and genetic characterization of toxin A variant strains of Clostridium difficile among adults and children with diarrhea in France [J].
Barbut, F ;
Lalande, V ;
Burghoffer, B ;
Thien, HV ;
Grimprel, E ;
Petit, JC .
JOURNAL OF CLINICAL MICROBIOLOGY, 2002, 40 (06) :2079-2083
[10]   Epidemiology of Clostridium difficile-associated infections [J].
Barbut, F ;
Petit, JC .
CLINICAL MICROBIOLOGY AND INFECTION, 2001, 7 (08) :405-410